
Gallus BioPharmaceutical Aquires CMO Laureate Biopharmaceutical Services
he CMO Gallus BioPharmaceutical has acquired the biologics CMO Laureate Biopharmaceutical Services.
Gallus has clinical and commercial suites at both sites, with 50-L to 2000-L GMP single-use platforms from Xcellerex and HyClone in addition to 50-L to 2000L fixed and flexible stainless-steel bioreactors and associated downstream purification for drug substances.
Source:
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.